SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric ETV6-RUNX1 B-Acute Lymphoblastic Leukemia Patients. The gene discussed is ETV6; the disease is acute lymphoblastic leukemia.